152 related articles for article (PubMed ID: 28714030)
21. Biological characteristics of Taxol‑resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53.
Liu Q; Sui R; Li R; Miao J; Liu J
Mol Med Rep; 2015 Feb; 11(2):1292-7. PubMed ID: 25351378
[TBL] [Abstract][Full Text] [Related]
22. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
[TBL] [Abstract][Full Text] [Related]
23. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
24. Tetrandrine Reverses Paclitaxel Resistance in Human Ovarian Cancer via Inducing Apoptosis, Cell Cycle Arrest Through β-Catenin Pathway.
Jiang L; Hou R
Onco Targets Ther; 2020; 13():3631-3639. PubMed ID: 32431514
[TBL] [Abstract][Full Text] [Related]
25. Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells.
Pitchakarn P; Umsumarng S; Mapoung S; Ting P; Temviriyanukul P; Punfa W; Pompimon W; Limtrakul P
J Nat Med; 2017 Oct; 71(4):693-702. PubMed ID: 28639112
[TBL] [Abstract][Full Text] [Related]
26. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
27. Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin.
Dia VP; Pangloli P
J Cell Physiol; 2017 Feb; 232(2):391-401. PubMed ID: 27198989
[TBL] [Abstract][Full Text] [Related]
28. Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).
Huang RY; Kuay KT; Tan TZ; Asad M; Tang HM; Ng AH; Ye J; Chung VY; Thiery JP
Oncotarget; 2015 Sep; 6(26):22098-113. PubMed ID: 26061747
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
31. LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465.
Zhao H; Wang A; Zhang Z
J Biochem; 2020 Aug; 168(2):171-181. PubMed ID: 32211849
[TBL] [Abstract][Full Text] [Related]
32. Decreased long non-coding RNA SPRY4-IT1 contributes to ovarian cancer cell metastasis partly via affecting epithelial-mesenchymal transition.
Yu J; Han Q; Cui Y
Tumour Biol; 2017 Jul; 39(7):1010428317709129. PubMed ID: 28691641
[TBL] [Abstract][Full Text] [Related]
33. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
Tang J; Cao L; Yi H; Tang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
[TBL] [Abstract][Full Text] [Related]
34. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
[TBL] [Abstract][Full Text] [Related]
35. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.
Han ML; Zhao YF; Tan CH; Xiong YJ; Wang WJ; Wu F; Fei Y; Wang L; Liang ZQ
Acta Pharmacol Sin; 2016 Dec; 37(12):1606-1622. PubMed ID: 27840408
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer.
Fu Z; Wang C; Chen Y; Zhang X; Wang X; Xie X
Pathol Res Pract; 2019 Nov; 215(11):152625. PubMed ID: 31540773
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
39. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
